Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cascadian Therapeutics, Inc. | v59102exv99w1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2011
ONCOTHYREON INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation) |
001-33882 (Commission File Number) |
26-0868560 (IRS Employer Identification No.) |
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
(206) 801-2100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On May 4, 2011, Oncothyreon Inc. (the “Company”) closed the public offering (the “Offering”)
of 11,500,000 shares of its common stock at a price of $4.00 per share, less underwriting discounts
and commissions. The Offering included the sale of 1,500,000 shares pursuant to the underwriters’
over-allotment option. On May 4, 2011, the Company issued a press release announcing the exercise
of the underwriters’ over-allotment option and the closing of the Offering. A copy of the press
release is attached as Exhibit 99.1 to this report and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached
exhibit is deemed to have been filed with the Securities and Exchange Commission:
| Exhibit | ||||
| Number | Description | |||
| 99.1 | Press Release issued by Oncothyreon Inc. dated May 4, 2011. |
|||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ONCOTHYREON INC. |
||||
| By: | /s/ Julia M. Eastland | |||
| Julia M. Eastland | ||||
| Chief Financial Officer, Secretary and Vice President of Corporate Development | ||||
Date: May 4, 2011
EXHIBIT INDEX
| Exhibit | ||||
| Number | Description | |||
| 99.1 | Press Release issued by Oncothyreon Inc. dated May 4, 2011. |
|||